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Estrogens attenuate renal injury induced by ischemia/
reperfusion (I/R), an effect that is related to nitric oxide
production in the post-ischemic kidney. The compound
17b-estradiol (E2-b) acting via estrogen receptors (ERs) is
known to activate endothelial nitric oxide synthase (eNOS)
through the phosphatidylinositol-3 kinase (PI3K)/Akt
pathway. We determined if this pathway contributes to the
renoprotective effect of E2-b in the uninephrectomized
ischemia reperfusion rat model of acute renal injury.
Treatment with E2-b suppressed the I/R-induced increases in
blood urea nitrogen, plasma creatinine, urine flow, and
fractional excretion of sodium while augmenting creatinine
clearance, renal blood flow, and urine osmolality, indicating
attenuation of renal injury. Phosphorylation of Akt and eNOS
protein was significantly increased 30–60 min after
reperfusion in estradiol-treated compared to vehicle-treated
rats. The protective effects of E2-b and protein
phosphorylation were reversed by the PI3K inhibitor
wortmannin or the ER antagonist tamoxifen. Furthermore,
the E2-b-induced renoprotective effects were not seen in
eNOS knockout mice with renal injury. We conclude that the
E2-b-induced renoprotective effect is due to activation of the
PI3K/Akt pathway followed by increased eNOS
phosphorylation in the post-ischemic kidney.
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It is well known that the incidence of cardiovascular diseases
is lower in women prior to menopause compared with men
and postmenopausal women.1 Estrogen replacement therapy
attenuates the incidence of cardiovascular events in post-
menopausal women. Recently, it is becoming increasingly
appreciated that gender differences exist in susceptibility to
and/or mortality from ischemia/reperfusion (I/R)-induced
injuries in heart,2,3 liver,4 and kidney.5,6 There are consistent
findings that females are less susceptible to these I/R-induced
injuries compared with males. Indeed, Harada et al.4 showed
that the protective effect observed in female mice against
reduced-size liver I/R injury was attenuated by ovariectomy
or administration of an estrogen antagonist. Park et al.5
demonstrated that orchiectomy decreased the kidney sus-
ceptibility to I/R-induced acute renal failure (ARF) in male
mice. Thus, sex hormones may be the important determinant
in these gender differences of various diseases.
The molecular mechanisms underlying the I/R-induced
ARF are not fully understood, but several casual factors are
contributive to the pathogenesis of this renal lesion.7 In the
post-ischemic kidney, there is increased reactivity to
vasoconstrictive agents and decreased vasodilatory responses
in arterioles compared with normal kidney.8 Endothelial
dysfunction is an important component of initiating and
continuing renal tubular epithelial injury and contributes to
the pathogenesis of I/R-induced renal injury.9 In addition,
endothelial injury aggravates the inflammatory response
through loss of normal nitric oxide (NO) production due
to inhibition of endothelial NO synthase (eNOS).
NO works as an important endogenous modulator of I/R-
induced renal injury.10 NO precursor L-arginine has been
reported to ameliorate the post-ischemic ARF.11 Further-
more, inhibition of NOS was seen to aggravate the renal I/R
injury.12 We have demonstrated that pre-ischemic treatment
with FK409, a spontaneous NO releaser, exerted a remarkable
protective effect against the post-ischemic ARF.13 Taken
together, NO seems to function as a renoprotective factor
against the I/R-induced renal injury.
Recently, we have reported that 17b-estradiol (E2-b)
protects the kidney against the post-ischemic injury in male
rats and that the protective effects of E2-b were markedly
attenuated by the pretreatment with NG-nitro-L-arginine
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methyl ester (L-NAME), a non-selective NOS inhibitor.14
Furthermore, we noted that the renal NO2
/NO3
 (NOx) level
was markedly reduced during ischemia and after reperfusion
and that the reduced level recovered rapidly to the basal level
in the E2-b-treated ARF rats compared with the vehicle-
treated ARF rats. These findings suggest that E2-b has a
protective effect against the post-ischemic ARF by increasing
the production of NO. However, mechanisms underlying E2-
b-induced NO production in the post-ischemic kidney are
not elucidated.
E2-b is known to increase the endothelial NO production,
which is contributive to its vasoprotective action. This can be
explained at least in part by increases in the eNOS mRNA
expression and its protein level. These effects are consistent
with the classic genomic mechanism of estrogen receptors
(ERs) action that involves transcription of target genes in the
nucleus. On the other hand, there is growing evidence that
ERs also mediate non-genomic effects by activating cell
signaling pathways outside the nucleus. A number of cell
culture studies have suggested that E2-b rapidly increases NO
release by stimulating the phosphatidylinositol-3 kinase
(PI3K)/Akt pathway, depending on ERs.15–18
Thus, the purpose of the present study is to determine
whether E2-b prevents I/R-induced renal injury by stimulat-
ing the PI3K/Akt pathway, resulting in the increased
production of NO in the post-ischemic kidney.
RESULTS
Effects of E2-b and wortmannin on renal function after the I/R
As shown in Figure 1, the renal function of rats subjected to
45-min ischemia and reperfusion showed marked deteriora-
tion when measured 1 day after reperfusion. As compared
with sham-operated rats, vehicle-treated ARF rats showed
significant increases in blood urea nitrogen (BUN), creatinine
levels in plasma (Pcr), urine flow, and fractional excretion of
sodium (FENa), and significant decreases in creatinine
clearance (Ccr) and urinary osmolality (Uosm). Administra-
tion of E2-b to ARF rats 15 min before reperfusion markedly
attenuated the I/R-induced renal dysfunction. Pre-ischemic
treatment with wortmannin (10 min before ischemia), a PI3K
inhibitor, markedly attenuated the protective effects of E2-b.
Wortmannin alone did not affect the renal dysfunction
induced by I/R.
Effects of E2-b and wortmannin on histological renal damage
after the I/R
Histological examinations revealed severe lesions in the
kidney of vehicle-treated ARF rats (1 day after the 45-min
ischemia and reperfusion). These changes were characterized
by proteinaceous casts in tubuli in the inner zone of medulla
(scores 3.67±0.33), medullary congestion, and hemorrhage
in the outer zone inner stripe of medulla (scores 3.33±0.33),
and tubular necrosis in the outer zone outer stripe of medulla
(scores 3.67±0.33). Treatment with E2-b of ARF rats
attenuated the development of all these lesions, but the
combination with wortmannin reversed the protective effect
of E2-b (Figure 2 and Table 1).
Effects of E2-b and tamoxifen on renal function after the I/R
As shown in Figure 3, the pre-ischemic treatment with
tamoxifen (60 min before ischemia), an ERs antagonist,
abolished the E2-b-induced renoprotective effects. In con-
trast, tamoxifen alone did not affect the renal dysfunction
induced by I/R (data not shown).
Effects of E2-b and tamoxifen on histological renal damage
after the I/R
The pre-ischemic treatment with tamoxifen also suppressed
the protective effect of E2-b on histological renal damage
after I/R (Table 2).
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Figure 1 | Effects of E2-b and wortmannin (wt) on (a) BUN, (b) Pcr, (c) Ccr, (d) urine flow (UF), (e) FENa, and (f) Uosm 24 h after I/R. E2-b
(100mg kg1, i.v.) was given 15 min before reperfusion, and wortmannin (10mg kg1, i.v.) was given 10 min before ischemia. Each column and
bar represents the mean±s.e.m. wwPo0.01, compared with sham rats. *Po0.05, **Po0.01, compared with vehicle-treated ARF rats.
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Time course of phosphorylated-Akt (Ser473) and
phosphorylated-eNOS (Ser1177 and Thr495) protein
expression in the post-ischemic kidneys with or without
E2-b treatment
Expression of renal phosphorylated-Akt (Ser473) protein tended
to increase transiently in the post-ischemic kidney com-
pared with that of sham rat, but thereafter the increased level
declined gradually to sham level. In E2-b-treated ARF rats, there
were significant high levels of phosphorylated-Akt protein
expression at 10, 30, and 60 min after reperfusion compared
with vehicle-treated ARF rats (Figure 4). Furthermore, phos-
phorylated-eNOS (Ser1177) protein expression was also increased
significantly in E2-b-treated ARF rats in the same manner as
described above, compared with that of vehicle-treated ARF rats,
in which this protein expression slightly and gradually increased
after reperfusion (Figure 5). The phosphorylated-eNOS (Thr495,
a negative regulatory site) expression was also increased
transiently and slightly in the post-ischemic kidney, but there
is no difference with or without E2-b treatment (data not
shown). Neither I/R itself nor E2-b treatment changed total Akt
and eNOS protein levels (Figures 4 and 5).
Time course of constitutive NOS activity in the post-ischemic
kidneys with or without E2-b treatment
Changes of NOS activity were evaluated in kidneys exposed
to I/R with or without E2-b treatment. As shown in Table 3,
the constitutive NOS (cNOS) activities in vehicle-treated
ARF rats were slightly increased at 60 min after reperfusion
compared with sham-operated rats. In contrast, the cNOS
activities in E2-b-treated ARF rats were increased gradually
and significant changes were observed at 60 min after
reperfusion. Inducible NOS activity was not detected in
kidneys of sham-operated rats and ARF rats with or without
E2-b treatment (data not shown).
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a b c d
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Figure 2 | Light microscopy of (a–d) the inner zone of medulla, (e–h) the outer zone inner stripe, and (i–l) the outer zone outer stripe
of kidneys of ARF rats treated with (b, f, and j) vehicle, (c, g, and k) E2-b or (d, h, and l) E2-bþwortmannin (wt), and (a, e, and i)
sham-operated rats. E2-b (100 mg kg
1, i.v.) was given 15 min before reperfusion, and wortmannin (10 mg kg1, i.v.) was given 10 min before
ischemia. Arrows indicate (b and d) severe proteinaceous casts in tubuli, (f and h) congestion and hemorrhage, and (j and l) tubular necrosis
(hematoxylin–eosin staining, original magnification  200).
Table 1 | Effects of E2-b and wt on histopathological changes in kidneys of ARF rats
Vehicle-treated ARF (n=6) ARF+E2-b (n=5) ARF+E2-b+wt (n=6)
Proteinaceous casts in tubuli 3.67±0.33 2.00±0.32* 2.67±0.42
Medullary congestion 3.33±0.33 2.00±0.45* 3.17±0.40
Tubular necrosis 3.67±0.33 1.80±0.20** 3.17±0.31
ARF, acute renal failure; E2-b, 17b-estradiol; wt, wortmannin.
Each value represents the mean±s.e.m. of histopathological score. Grades of score: no change (0), mild (1), moderate (2), severe (3), very severe (4). *Po0.05, **Po0.01,
compared with vehicle-treated ARF rats.
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Effects of E2-b, wortmannin, and tamoxifen on expression of
phosphorylated-Akt (Ser473) and phosphorylated-eNOS
(Ser1177) protein
As shown in Figures 6 and 7, the increases in both
phosphorylated-Akt (Ser473) and phosphorylated-eNOS (Ser1177)
proteins at 30 and 60 min after reperfusion in E2-b-treated ARF
rats were abolished by pre-ischemic treatment with wortmannin.
Similarly, the pre-ischemic treatment with tamoxifen given to ARF
rats completely suppressed the E2-b-induced increments of both
proteins at 30 and 60 min after reperfusion (Figures 8 and 9).
Time course of renal blood flow in the post-ischemic kidneys
with or without E2-b treatment
Changes of renal blood flow were evaluated in anesthetized
(sodium thiobutabarbital: inactin, 100 mg kg1, intraperito-
neal (i.p.)) rats exposed to I/R with or without E2-b
treatment, using an electromagnetic flow probe (1.0 mm in
diameter, Nihon Kohden, Tokyo, Japan) connected to a
square-wave flowmeter (MFV-2100; Nihon Kohden). As
shown in Figure 10, renal blood flow in the post-ischemic
kidneys gradually restored and reached a plateau at 1 h after
the start of reperfusion, but E2-b treatment significantly
produced an early recovery at 10–30 min after reperfusion.
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Figure 3 | Effects of E2-b and tamoxifen (tam) on (a) BUN, (b) Pcr, (c) Ccr, (d) urine flow (UF), (e) FENa, and (f) Uosm 24 h after I/R. E2-b
(100mg kg1, i.v.) was given 15 min before reperfusion, and tamoxifen (5 mg kg1, i.v.) was given 60 min before ischemia. Each column and bar
represents the mean±s.e.m. wPo0.01, wwPo0.01, compared with sham rats. *Po0.05, **Po0.01, compared with vehicle-treated ARF rats.
Table 2 | Effects of E2-b and tam on histopathological changes in kidneys of ARF rats
Vehicle-treated ARF (n=7) ARF+E2-b (n=7) ARF+E2-b+tam (n=4)
Proteinaceous casts in tubuli 3.71±0.29 1.86±0.34** 3.50±0.29
Medullary congestion 3.71±0.29 2.00±0.38** 3.50±0.29
Tubular necrosis 3.86±0.14 2.00±0.22** 3.25±0.25
ARF, acute renal failure; E2-b, 17b-estradiol; tam, tamoxifen.
Each value represents the mean±s.e.m. of histopathological score. Grades of score: no change (0), mild (1), moderate (2), severe (3), very severe (4). **Po0.01, compared with
vehicle-treated ARF rats.
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Figure 4 | Time course of total Akt and phosphorylated-Akt
(p-Akt, Ser473) expression in the kidney of vehicle-treated or
E2-b-treated ARF rats. E2-b (100 mg kg
1, i.v.) was given 15 min
before reperfusion. Mean density values are presented as fold
difference compared with sham-operated rats. Each point and
bar represents the mean±s.e.m. **Po0.01, compared with
vehicle-treated ARF rats.
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Effects of E2-b on renal function after the I/R in wild-type mice
and eNOS/ mice
Renal function (BUN and Pcr) of wild-type mice subjected to
45-min ischemia and reperfusion showed a marked dete-
rioration when measured 48 h after reperfusion. Administra-
tion of E2-b to ARF mice 15 min before reperfusion markedly
attenuated the I/R-induced renal dysfunction. eNOS/ mice
also showed the same degree of I/R-induced renal dysfunc-
tion, but this renal damage was not improved by treatment
with E2-b (Figure 11).
Effects of E2-b on renal function after the I/R in bilateral
ischemia model
In separate experiments, the effects of E2-b on renal
dysfunction induced by the I/R were examined using a
bilateral ischemia model without prior uninephrectomy.
As shown in Figure 12, renal function (BUN and Pcr) of
rats subjected to 45-min ischemia and reperfusion showed
a similar deterioration when measured 1 day after reperfusion
in cases of one kidney model. The administration of
E2-b 15 min before reperfusion at lower dose (10 mg kg
1,
i.v.) significantly attenuated the I/R-induced renal
dysfunction, but higher doses (20, 100 mg kg1, i.v.) failed
to improve it.
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Figure 5 | Time course of total eNOS and phosphorylated-eNOS
(p-eNOS, Ser1177) expression in the kidney of vehicle-treated or
E2-b-treated ARF rats. E2-b (100 mg kg
1, i.v.) was given 15 min
before reperfusion. Mean density values are presented as fold
difference compared with sham-operated rats. Each point and bar
represents the mean±s.e.m. *Po0.05, **Po0.01, compared with
vehicle-treated ARF rats.
Table 3 | Effects of E2-b on cNOS activity in post-ischemic
kidney
Reperfusion
time (min)
Vehicle-treated
ARF (% of sham) ARF+E2-b
30 101.3±7.7 134.7±13.2
60 135.6±10.5 182.9±11.5*
ARF, acute renal failure; cNOS, constitutive NOS; E2-b, 17b-estradiol.
Each value represents the mean±s.e.m. of cNOS activity as fold difference
compared with sham-operated rats. Inducible NOS activity was not detected in all
groups. *Po0.05, compared with vehicle-treated ARF rats.
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Figure 6 | Effects of E2-b and wortmannin (wt) on
phosphorylated-Akt (p-Akt, Ser473) and phosphorylated-eNOS
(p-eNOS, Ser1177) expression in the kidney 30 min after
reperfusion. E2-b (100 mg kg
1, i.v.) was given 15 min before
reperfusion, and wortmannin (10 mg kg1, i.v.) was given 10 min
before ischemia. (a) Representative western blots for p-Akt, total Akt,
and actin. (b) Representative western blots for p-eNOS, total eNOS,
and actin. Mean density values are presented as fold difference
compared with vehicle-treated ARF rats. Each column and bar
represents the mean±s.e.m. **Po0.01, compared with vehicle-
treated ARF rats.
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Figure 7 | Effects of E2-b and wortmannin (wt) on phosphorylated-
Akt (p-Akt, Ser473) and phosphorylated-eNOS (p-eNOS, Ser1177)
expression in the kidney 60 min after reperfusion. E2-b
(100mg kg1, i.v.) was given 15 min before reperfusion, and
wortmannin (10 mg kg1, i.v.) was given 10 min before ischemia.
(a) Representative western blots for p-Akt, total Akt, and actin.
(b) Representative western blots for p-eNOS, total eNOS, and actin.
Mean density values are presented as fold difference compared
with vehicle-treated ARF rats. Each column and bar represents the
mean±s.e.m. **Po0.01, compared with vehicle-treated ARF rats.
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DISCUSSION
We have recently noted that the ameliorative effect of E2-b
against the post-ischemic renal injury is accompanied by
increases in renal NOx levels and that a non-selective NOS
inhibitor can abolish the beneficial effects of E2-b on the
ischemic ARF.14 Thus, the increasing effect of E2-b on the
renal NO production seems to be closely related to its
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Figure 8 | Effects of E2-b and tamoxifen (tam) on
phosphorylated-Akt (p-Akt, Ser473) and phosphorylated-eNOS
(p-eNOS, Ser1177) expression in the kidney 30 min after
reperfusion. E2-b (100mg kg
1, i.v.) was given 15 min before
reperfusion, and tamoxifen (5 mg kg1, i.v.) was given 60 min before
ischemia. (a) Representative western blots for p-Akt, total Akt, and
actin. (b) Representative western blots for p-eNOS, total eNOS, and
actin. Mean density values are presented as fold difference compared
with vehicle-treated ARF rats. Each column and bar represents the
mean±s.e.m. **Po0.01, compared with vehicle-treated ARF rats.
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Figure 9 | Effects of E2-b and tamoxifen (tam) on
phosphorylated-Akt (p-Akt, Ser473) and phosphorylated-eNOS
(p-eNOS, Ser1177) expression in the kidney 60 min after
reperfusion. E2-b (100mg kg
1, i.v.) was given 15 min before
reperfusion, and tamoxifen (5 mg kg1, i.v.) was given 60 min before
ischemia. (a) Representative western blots for p-Akt, total Akt, and
actin. (b) Representative western blots for p-eNOS, total eNOS, and
actin. Mean density values are presented as fold difference compared
with vehicle-treated ARF rats. Each column and bar represents the
mean±s.e.m. **Po0.01, compared with vehicle-treated ARF rats.
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Figure 10 | Time course of renal blood flow in the post-ischemic
kidneys with or without E2-b treatment. E2-b (100 mg kg
1, i.v.) was
given 15 min before reperfusion. Each point and bar represents the
mean±s.e.m. *Po0.05, compared with vehicle-treated ARF rats.
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Figure 12 | Effects of E2-b on (a) BUN and (b) Pcr 24 h after I/R in
bilateral ischemia models. E2-b (10–100 mg kg
1, i.v.) was given
15 min before reperfusion. Each column and bar represents the
mean±s.e.m. *Po0.05, **Po0.01, compared with vehicle-treated
ARF rats.
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renoprotective effects. We and others have demonstrated that
endogenous and/or exogenous NO protects the kidney from
I/R-induced renal dysfunction and tissue injury.10–13
In this study, we investigated whether the PI3K/Akt pathway
is positioned upstream to the enhancement of NO production
in mechanisms underlying the renoprotective effects of E2-b.
Pretreatment with wortmannin, a PI3K inhibitor, or tamox-
ifen, an ER antagonist, abolished the E2-b-induced renal
protection observed 24 h after reperfusion. Furthermore, we
found that E2-b treatment markedly increased the levels of
renal phosphorylated-Akt and phosphorylated-eNOS (Ser1177)
proteins in an early phase after reperfusion, and the
augmentation of both proteins was also attenuated markedly
by the combination with wortmannin or tamoxifen. Taken
together, it seems likely that E2-b activates the PI3K/Akt
pathway, resulting in the increment of eNOS phosphorylation
(Ser1177) in the post-ischemic kidney, which plays a crucial role
in the protective effects of E2-b against I/R-induced renal
injury. This view is supported by the findings that cNOS
activities were significantly increased by E2-b treatment at the
same time points as seen in eNOS phosphorylation. Moreover,
the treatment with E2-b failed to improve the I/R-induced
renal dysfunction in eNOS/ mice, in contrast to the cases in
wild-type mice, thereby suggesting that the eNOS component
is essential to the renoprotective effect of E2-b.
Mechanisms of increased production of NO by E2-b have
been reported in various studies.19 One possible mechanism
can be explained in part through the genomic action via ERs;
when cultured endothelial cells20–22 or cardiac myocytes23
were exposed to E2-b for 8–24 h, there were marked increases
in NOS enzymatic activity and eNOS protein expression,
accompanied by the elevation of eNOS mRNA levels, and
these changes were abolished by ERs antagonists. In contrast,
multiple pathways activated through the rapid, non-genomic
action via membrane-associated ERs have been known to
increase NO production. In endothelial cells, E2-b caused a
rapid (5–15 min) stimulation of eNOS activity, and this
response was attenuated by an ERs antagonist but not by
inhibition of gene transcription.24 Simoncini et al.16 have
reported that ERa interacts with a subunit of PI3K and
stimulates it, leading to the activation of Akt and eNOS. In
our study, treatment with E2-b rapidly enhanced the
phosphorylation of Akt and eNOS (Ser1177) and increased
cNOS activities in the post-ischemic kidney, without
changing total level of both proteins, suggesting the non-
genomic action of E2-b. However, we cannot rule out the
possible involvement of the genomic mechanisms in the E2-
b-induced renal protection. A long-term effect of E2-b on
renal injury and eNOS mRNA levels in the post-ischemic
kidney should be examined.
Our results are in agreement with the view that NO exerts
a renoprotective effect against the I/R-induced renal in-
jury.12,13,25 We have previously noted that treatment with E2-
b in the ischemic ARF rats enhanced renal NOx production
in an early phase after reperfusion.14 In this study, E2-b
treatment resulted in more rapid return of renal blood flow
diminished by the ischemia. This restoration of blood flow
seems likely to be due to the E2-b-induced eNOS activation
and NO production and may be at least partly contributive to
the renoprotective effect of E2-b. Moreover, we have noted
that both exogenous and endogenous NO have protective
effects against I/R-induced renal dysfunction and tissue
injury, through the suppression of endothelin-1 overproduc-
tion,26 which is known to be one of the major causal factors
of this disease,27,28 and that the improvement of ischemic
ARF by E2-b treatment was followed by the suppression of
endothelin-1 overproduction in the post-ischemic kidney.29
Most recently, we demonstrated that the pre-ischemic
treatment with exogenous NO markedly suppressed the renal
O2
 production augmented by I/R, following the attenuation
of neutrophil infiltration.30 Neutrophil infiltration/migration
appears to contribute to the post-ischemic ARF through
various mechanisms.31,32 Taken together, E2-b given prior to
the reperfusion may exert a renoprotective effect via
NO-related multifunctional mechanisms.
In animal models, sex differences have been widely
indicated in I/R injury in various organs, including the
kidney. Mu¨ller et al.6 demonstrated that kidneys of male
mature rats are more susceptible to post-ischemic injury than
those of females. Moreover, they found that castration and
sexual immaturity did not affect the I/R injury produced in
females but decreased the injury produced in males, thereby
suggesting that testosterone plays a more important role in
these sex differences than estrogen. However, E2-b treatment
of males but not testosterone treatment of females markedly
improves the post-ischemic survival. Park et al.5 also
observed similar sex differences and E2-b-induced beneficial
action in male ARF rats. Furthermore, they demonstrated
that testosterone administration increased susceptibility to
renal I/R in females, ovariectomized females, and castrated
males, in contrast to findings by Mu¨ller et al.6 Thus,
testosterone seems to play a crucial role in sex differences
in I/R-induced renal injury, although there are some
discrepancies. In contrast, we demonstrated the beneficial
effect of E2-b administration to male ARF rats and its
signaling pathway. Further studies are needed to clarify
whether estrogen is also an important determinant of the sex
difference in renal I/R injury.
Clinical studies looking at outcomes in ARF patients have
also shown that men have twice the mortality of women.33,34
Despite improvements in intensive care and dialytic techno-
logy, there were no meaningful improvements in patient
survival over the past three decades. The I/R-induced ARF is
considered as an important determinant of allograft survival
after renal transplantation. It is reported that the donor and/
or recipient gender influences graft survival in the transplant-
ation of some organs.35,36 For example, a study dealing with
the long-term survival outcomes of liver transplant recipients
has shown that patient survival is significantly better in
female recipients than in males.36 Taken together, there is a
possibility of E2-b as a target for protective strategies to avoid
ARF and to increase the rates of graft survival.
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In our study, I/R was performed using uninephrectomized
animals to investigate the renal dysfunction and tissue
damage in one kidney; since collected urine is derived from
one kidney, we can determine the renal excretory function of
the kidney. Bilateral renal ischemia models have been
generally used in a number of experiments, but uninephrec-
tomized ischemia models are also well utilized. However, a
previous study indicated that there are gender differences in
remnant kidney growth, morphology, and function in rats
two months after uninephrectomy.37 Thus, one may doubt a
possibility that the effects of E2-b and related agents are
influenced by uninephrectomy. Therefore, we evaluated
whether E2-b could attenuate the I/R-induced renal dysfunc-
tion in the bilateral ischemia model, and found that the lower
dose (10 mg kg1, i.v.) significantly attenuated the I/R-
induced renal dysfunction, but higher doses (20, 100 mg kg1,
i.v.) failed to improve it. In our previous study,29 E2-b at
20–100 mg kg1 produced a dose-dependent renoprotective
effect in uninephrectomized ischemia models. The reason for
the difference in the dose responses to E2-b between bilateral
and uninephrectomized models is unclear, but there is a
report indicating that E2-b treatment causes adverse effects
on the renovasculature in a rodent model of renal injury.38 In
addition, studies examining the effects of E2-b treatment on
renal function have demonstrated both beneficial and adverse
effects.38–41 In contrast, there is convincing evidence indicat-
ing that testosterone is a more important factor than estrogen
in the pathogenesis of bilateral I/R injury,5 thereby suggesting
the possibility that testosterone may mask the renoprotective
effect of E2-b in this model. Taken together, the renoprotec-
tive effects of E2-b against post-ischemic renal injury
may be dependent on differences in experimental conditions
and models. Based on that bilateral ischemia is perhaps
more relevant to the ischemic ARF injury in humans,
further studies to evaluate the renoprotective effect of E2-b
and its mechanisms in the bilateral ischemia model are
needed.
In conclusion, our findings using the uninephrectomized
ischemia model demonstrate that E2-b prevents I/R-induced
renal injury by stimulating the PI3K/Akt pathway, resulting
in the increment of phosphorylated-eNOS expression. More-
over, we indicated that the PI3K/Akt pathway is activated in
an ER-dependent manner. The possibility that these reno-
protective mechanisms of E2-b are involved in sex differences
in the ischemic ARF warrants further attention.
MATERIALS AND METHODS
Animals and experimental design
Rats. Male Sprague–Dawley rats (10 weeks of age; Japan SLC,
Shizuoka, Japan) weighing 280–320 g were used. The animals were
housed in a light-controlled room with a 12-h light/dark cycle and
were allowed ad libitum access to food and water. Experimental
protocols and animal care methods in the experiments were
approved by the Experimental Animal Research Committee at
Osaka University of Pharmaceutical Sciences. Two weeks before
the study (at 8 weeks of age), the right kidney was removed
through a small flank incision under pentobarbital anesthesia
(50 mg kg1, i.p.). After a 2-week recovery period, uninephrecto-
mized rats were divided into five groups: (1) sham-operated
control, (2) vehicle-treated ischemic ARF, (3) ischemic ARF treated
with E2-b (100 mg kg
1, i.v.), (4) ischemic ARF treated with E2-b
(100 mg kg1, i.v.) and wortmannin (10 mg kg1, i.v.), and (5)
ischemic ARF treated with wortmannin (10 mg kg1, i.v.). To induce
ischemic ARF, the rats were anesthetized (sodium pentobarbital,
50 mg kg1, i.p.), and the left kidney was exposed through a small
flank incision. The left renal artery and vein were occluded with a
non-traumatic clamp for 45 min. At the end of the ischemic period,
the clamp was released for blood reperfusion.
In this study, the I/R was performed using uninephrectomized
animals to investigate the renal dysfunction and tissue damage in
one kidney; since collected urine is derived from one kidney, we can
determine the renal excretory function of the kidney. Previous
studies have been carried out in the same manner.13,14,26,28–30
However, in some experiments, the effects of E2-b (10–100mg kg
1,
i.v.) on renal dysfunction induced by I/R were also examined using
the bilateral ischemia model without prior uninephrectomy, in view
of a possibility that the effects of E2-b are influenced by
uninephrectomy.
E2-b or vehicle (a mixture of 2.5% ethanol, 30% polyethylene
glycol 400, and 67.5% saline) in a volume of 1 ml kg1 was injected
15 min before reperfusion. Wortmannin or vehicle (2.5% dimethyl
sulfoxide and 97.5% saline) was injected 10 min before ischemia. In
sham-operated control rats, the kidney was treated identically,
except for the clamping. Animals exposed to 45 min ischemia were
housed in metabolic cages at 24 h after reperfusion, and thereafter
5-h urine samples were taken and blood samples were drawn from
the thoracic aorta at the end of the urine collection period. The
plasma was separated by centrifugation. These samples were used for
measurements of renal functional parameters. The kidneys were
excised and examined using a light microscope.
In another set of experiments, we evaluated whether E2-b-
induced renoprotective effects were reversed by the combination
with tamoxifen, an ERs antagonist. The experiments were
performed in the same manner as described above. Briefly,
uninephrectomized rats were divided into four groups: (1) sham-
operated control, (2) vehicle-treated ischemic ARF, (3) ischemic
ARF treated with E2-b (100 mg kg
1, i.v.), and (4) ischemic ARF
treated with E2-b (100 mg kg
1, i.v.) and tamoxifen (5 mg kg1, i.v.).
E2-b was injected 15 min before reperfusion, and tamoxifen or
vehicle (a mixture of 30% ethanol and 70% polyethylene glycol 400)
in a volume of 1 ml kg1 was injected 60 min before ischemia.
Moreover, in separate experiments, the left kidneys were
obtained at 10, 30, 60, 180, and 360 min after I/R, frozen using
liquid nitrogen, and used for western blot analysis and NOS activity
measurements.
Mice. Male C57bl/6J wild-type and eNOS/ mice (10 weeks of
age; The Jackson Laboratory, Bar Harbor, ME, USA) weighing
20–25 g were used. Two weeks before the study (at 8 weeks of age),
the right kidney was removed through a small flank incision under
pentobarbital anesthesia (50 mg kg1, i.p.). After a 2-week recovery
period, uninephrectomized mice were divided into three groups: (1)
sham-operated control, (2) vehicle-treated ischemic ARF, and (3)
ischemic ARF treated with E2-b (100 mg kg
1, i.v.). Experimental
protocols and animal care methods in these experiments were the
same as in cases using rats, described above. Animals exposed to
45-min ischemia were housed in metabolic cages at 24 h after
reperfusion, and thereafter 24-h urine samples were taken and blood
samples were drawn from the thoracic aorta at the end of the urine
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collection period. These plasma and urine samples were used for
measurements of renal functional parameters.
Renal functional parameters
BUN and creatinine levels in plasma (Pcr) or urine were determined
using a commercial assay kit, the BUN-test-Wako and Creatinine-
test-Wako (Wako Pure Chemicals, Osaka, Japan), respectively.
Uosm was measured by freezing point depression (Fiske Associates,
Norwood, MA, USA). Urine and plasma sodium concentrations
were determined using a flame photometer (Hitachi, 205D,
Hitachinaka, Japan). Fractional excretion of sodium (FENa, %)
was calculated from the formula FENa¼UNaV/(PNaCcr) 100,
where UNaV is the urinary excretion of sodium and PNa is the plasma
sodium concentration.
Histological studies
Excised left kidneys were processed for light microscopic observa-
tion, according to the standard procedures. The kidneys were then
fixed in phosphate-buffered 10% formalin, after which the kidneys
were chopped into small pieces and embedded in paraffin wax, cut
at 4 mm, and stained with hematoxylin and eosin. Histological
changes were analyzed for proteinaceous casts, medullary conges-
tion, and tubular necrosis, as suggested by Caramelo et al.42 Tubular
necrosis and proteinaceous casts were graded as follows: no damage
(0), mild (1, unicellular, patchy isolated damage), moderate
(2, damage less than 25%), severe (3, damage between 25 and
50%), and very severe (4, more than 50% damage). The degree of
medullary congestion was defined by no congestion (0), mild
(1, vascular congestion with identification of erythrocytes by  400
magnification), moderate (2, vascular congestion with identification
of erythrocytes by  200 magnification), severe (3, vascular
congestion with identification of erythrocytes by  100 magnifica-
tion), and very severe (4, vascular congestion with identification of
erythrocytes by  40 magnification). The scoring of the histological
data was performed by independent observers in a double-blind
manner.
Western blotting
The kidneys were washed in pre-cooled saline containing 5 mM
EDTA, 2 mM b-glycerophosphate, 10 mM NaF, and 1 mM Na3VO4,
frozen under liquid nitrogen, and homogenized with Multi-Beads
Shocker (Yasuikikai, Osaka, Japan) in the buffer (62.5 mM Tris–HCl,
pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 1 mM ortho-
vanadate, 50 mM NaF, 20 mM b-glycerophosphate, 50 mM dithio-
threitol, 1 mM PMSF (phenylmethanesulfonylfluoride), 50 kIU ml1
aprotinine, 1 mg ml1 pepstatin, and 2 mg ml1 leupeptin). The
homogenate was then centrifuged, stored at 801C, and used for
western blotting. Equal amount of protein was fractionated using
7.5 or 10% sodium dodecyl sulfate-polyacrylamide gels. After
transfer to nitrocellulose membrane (Amersham Pharmacia Biotech,
Arlington Heights, IL, USA), the blots were blocked for 60 min at
room temperature with 5% nonfat dry milk in Tris-buffer saline
containing 0.1% Tween 20 (for eNOS, Akt, and phosphorylated-
Akt) or with Blocking One-P (Nacalai Tesque, Kyoto, Japan)
containing 50 mM NaF (for p-eNOS). After blocking, the blots were
incubated with primary antibodies (Akt, phosphorylated-Akt
(Ser473) and phosphorylated-eNOS (Ser1177 and Thr495) from Cell
Signaling Technology, Beverly, MA, USA; eNOS and actin from BD
Biosciences, San Jose, CA, USA) at 4 1C overnight. Membranes were
washed and then incubated with secondary antibodies (anti-rabbit
horseradish peroxidase-linked IgG for phosphorylated-eNOS, Akt
and phosphorylated-Akt from Zymed Laboratories, South San
Francisco, CA, USA; anti-mouse horseradish peroxidase-linked IgG
for eNOS and actin from Vector Laboratories, Burlingame, CA,
USA) at room temperature for 60 min. Detection was carried out
using an enhanced chemiluminescence western blotting kit (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA) and quantified by
using the NIH IMAGE.
Measurement of NOS activity
Ca2þ -dependent and -independent NOS activities (constitutive and
inducible NOS activities, respectively) were determined by measur-
ing the conversion of L-[3H]arginine to L-[3H]citrulline using an
NOS detection kit (NOS detection kit BOX-2; Sigma-Aldrich, St
Louis, MO, USA). Briefly, frozen kidneys were homogenized in a
buffer containing protease inhibitors. Homogenates were centri-
fuged and supernatant was utilized for the measurement of NOS
activities. The samples were incubated in assay buffer containing
0.323 mM L-[3H]arginine, 600 mM CaCl2, and 1 mM NADPH, in the
presence of an excess amount of calmodulin, at 37 1C for 30 min.
After stopping the reaction, the samples incubated in resin,
centrifuged, and radioactive activates of L-[3H]citrulline were
measured using a liquid scintillation counter (TRI-CARB; Packard,
Tokyo, Japan). To determine Ca2þ -independent NOS activity, the
assay was conducted in the presence of 10 mM EDTA without CaCl2.
Ca2þ -dependent NOS (cNOS) activity was calculated by subtract-
ing Ca2þ -independent NOS activity from total NOS activity.
Statistical analysis
Values are expressed as the mean±s.e.m. Relevant data were
processed by InStat (Graph-PAD Software for Science, San Diego,
CA, USA). For statistical analysis, we used the unpaired Student’s
t-test for two-group comparison and one-way analysis of variance
followed by Dunnett’s tests for multiple comparisons. Histological
data were analyzed using the Kruskal–Wallis non-parametric test
combined with Steel-type multiple comparison test. For all
comparisons, differences were considered significant at Po0.05.
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